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The ideal sclerosing agent would be effective
while causing minimal complications and associated
patient discomfort. Although only morrhuate sodi-
um, ethanolamine, and sodium tetradecyl sulfate
(Sotradecol) have been approved for use in the
United States by the Food and Drug Administration,
several other agents are often used. Although not
approved by the Food and Drug Administration,
hypertonic saline (HS) is one of the more com-
monly used sclerosing agents. HS is an osmotic
agent that exerts its effect by damaging the
endothelium, thereby causing scarring and adher-
ence of opposing vessel walls and obliteration of the
lumen. Although it is an effective treatment, it is
commonly associated with significant discomfort in
patients. In an effort to reduce the associated pain
and discomfort, some authors have suggested the
addition of lidocaine anesthetic to hypertonic saline
(LIDO),1,2 and this has been the practice in our
sclerotherapy clinic for some time. Although it
would seem advantageous, there are no studies in
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Purpose: The efficacy of sclerosing agents for the treatment of telangiectasias and reticu-
lar veins is well established. The injection of these agents is often associated with pain,
and it is not uncommon for sclerotherapists to include lidocaine with the sclerosants in
an attempt to reduce the pain associated with treatment. However, there are concerns
that this may reduce the overall efficacy of the treatment because of dilution of the scle-
rosant. Patient comfort and overall outcome associated with treatment using HS with
lidocaine (LIDO) versus that using HS alone was compared.
Methods: Forty-two patients were prospectively entered into the study and randomized
blindly to sclerotherapy with 23.4% HS or 19% LIDO. Study subjects and treating
physicians were blinded to the injection solution used. Injection sites were chosen for
veins ranging in size from 0.1 to 3 mm. Photographs of the area to be treated were
taken, and the patients rated their pain. They were then observed at regular intervals for
four months, and clinical data was collected. Thirty-five subjects completed the full fol-
low-up period, and photographs of the injected area were taken again. Three investiga-
tors blinded to the treatment assignment then evaluated the photographs and scored the
treatment efficacy according to a standardized system.
Results: In the HS group, 61.9% (13 of 21) patients rated their pain as none or mild,
whereas 90.5% (19 of 21) of patients in the LIDO group had no or mild discomfort.
This difference is significant, with a P value of .034. There was no difference in the over-
all efficacy of treatment between the two groups. The groups had similar rates of vein
thrombosis and skin necrosis.
Conclusion: Although lidocaine is often used with sclerosing agents, there are no previ-
ous reports in the literature to evaluate its effectiveness in reducing the pain experienced
by the patient. In this study, patients receiving LIDO experienced significantly less dis-
comfort at the time of injection than patients who received HS alone. There were no dif-
ferences in the effectiveness of treatment or in the incidence of complications between
the two groups. (J Vasc Surg 1999;29:479-83.)
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the literature that evaluate the effectiveness of this
treatment. HS and LIDO were compared with
respect to patient discomfort and overall efficacy of
treatment and complications.
MATERIALS AND METHODS
The protocol and informed consent statement
for this study were approved by the Good Samaritan
Hospital Institutional Review Board, and all
patients gave informed consent. Patients from the
Kachelmacher Memorial Clinic (Logan, Ohio) were
selected for inclusion in the study if they had telang-
iectasias measuring less than 1 mm or venulectasias
measuring between 1 and 3 mm. It is our standard
practice to inject all veins less than 5 mm with a
standard solution of HS. We do not use the com-
mon practice of injecting concentrations in rela-
tionship to vein size. Patients are not considered for
sclerotherapy if they have any evidence of chronic
venous insufficiency or edema. Patients must not be
pregnant or have a history of deep vein thrombosis
or superventricular tachycardia to be candidates for
injection therapy. Forty-two patients were random-
ly assigned in a double-blind fashion to one of two
treatment groups. Of the 35 patients who complet-
ed the study, 12 in the HS group and six in the
LIDO group had a vein size between 0 and 1 mm,
whereas seven patients in the HS group and 10
patients in the LIDO group had a vein size between
1 and 3 mm. These ratios were not significantly dif-
ferent (P = .1303).
Before the injections, color photographs were
taken of the areas to be treated, all of which were in
the lower extremities. One group received treatment
with 23.4% HS. The second group was treated with
LIDO, to achieve a final saline concentration of 19%.
The area injected was chosen and limited to a 5 cm
by 5 cm area, and the total volume injected was lim-
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Fig 1. An example of a telangiectasia, A, before and B, after treatment. There has been very
good resolution of the varicosities, with only slight pigmentation. An example of a larger (3
mm) vein is seen C, before treatment and D, after treatment. Again, there is good resolution
of the veins, with only slight pigmentation.
A B
C D
ited to a maximum of 2 mL. Injections were given by
means of 1 mL syringes with disposable 30 gauge
needles. Immediately after the injections, pressure
was held at the site with gauze. Postprocedure com-
pression was then initiated and continued for 96
hours with either elastic bandages or elastic compres-
sion stockings, based on patient preference.
At the initial injection visit, the subject was asked
to rate the discomfort experienced on a scale of 1 to
4. The rating scale was chosen to define distinct rat-
ing categories that we hoped would decrease the
ambiguity often associated with gauging pain (Table
I). At the same time, any immediate reactions to the
injection were recorded.
The subjects were then seen in the clinic for eval-
uation at one week, four weeks, and 12 weeks after
the initial visit. At these visits, the injection site was
examined for vein thrombosis, skin necrosis, mat-
ting/neovascularization, and hyperpigmentation. At
the final visit, photographs of the treated area were
taken again. The photographic technique used to
take the initial and final visit photographs was repro-
ducible, with a Nikon N8008 and the same distance,
same lenses, and same photographic film (Kodak
Color Print Film Gold 100 ASA).
The clinical response to treatment was evaluated by
means of a photographic score as determined by three
investigators blinded to the treatment assignment,
who compared the initiation and completion pictures
(Fig 1). The photographic score is the sum of scores
assigned to three factors: (1) the disappearance of vari-
cosities; (2) pigmentation; and (3) neovascularization.
A higher score denotes a better outcome. For analysis
purposes, the average of the three photographic scores
for each patient was then used as the indicator of over-
all effectiveness of treatment (Table II).
Data was analyzed by means of BMDP Statistical
Software (BMDP Statistical Software, Los Angeles,
Calif). Parametric statistical analysis was done by
means of the Student t test, and nonparametric com-
parisons were done by means of the Fisher exact test.
A P value of less than .05 represented a significant
difference.
RESULTS
Forty-two subjects were enrolled in the study
and initially received injections. Thirty-five complet-
ed the full follow-up protocol. The reasons why
seven patients did not complete the follow-up pro-
tocol are not known, and it is not known if this 17%
loss of the initial patients has impacted our analysis.
If a patient did not return for a visit, contact was
attempted first by phone then by a letter. Of the 42
patients who initially received injections, 21 received
HS and 21 received LIDO. In the HS cohort, 61.9%
rated their discomfort as none to mild (numerical
score 1 or 2), whereas 90.5% of subjects in the
LIDO group had no or mild discomfort (P = .034;
Fisher exact test). Comparisons of other levels of dis-
comfort did not reveal any statistically significant dif-
ferences (Table III). The level of discomfort experi-
enced by the subjects did not appear to be affected
by the size of the vein injected (less than 1 mm vs 1
to 3 mm; Table IV).
Nineteen subjects in the HS group finished the
study, and 16 subjects in the LIDO group finished
the study. There were no differences in the mean
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Table I. Level of discomfort
Descriptive assessment Numerical score
No pain 1
Mild pain 2
Moderate pain 3
Severe pain 4
Table II. Photographic score (sum of these three
factors, ranging from 3 to 13)
Descriptive assessment Numerical Score
Varicosities
Complete disappearance 5
Disappearance of majority 4
Partial disappearance 3
No change 2
Worse than at the start 1
Pigmentation
None 4
Tan 3
Light brown 2
Deep brown 1
Neovascularization
None 4
Slight 3
Moderate 2
Severe 1
Table III. Pain scores
Pain score HS group LIDO group
1 4 (19%) 5 (23%)
2 9 (43%) 14 (67%)
3 6 (28%) 2 (10%)
4 2 (10%) 0 (0%)
HS, Hypertonic saline alone; LIDO, hypertonic saline with lidocaine.
disappearance, pigmentation, and neovascularization
scores between the two groups. The overall photo-
graphic scores were also similar between the two
groups (HS, 11.07; LIDO, 11.43; P = .41; Student
t test; Table V). Also, photographs were taken with
the same camera, lighting, settings, distance, and
background drape.
The photographic scores of the three reviewers
exactly matched in 234 of the 315 individual scores
(74%). Although the range of scores differed slight-
ly between reviewers (7 to 13, 8 to 13, and 8 to 13),
the overall trend of scores for the individual patient’s
response to treatment were the same.
The incidence of vein microthrombosis was simi-
lar in the two groups, with four of 19 (21%) in the HS
group and four of 16 (25%) in the LIDO group hav-
ing vein microthrombosis (P = .55; Fisher exact test).
One episode of skin necrosis/ulceration occurred in
the HS group. This patient had a venule 0 to 1 mm
in size with a small slough less than 2 mm in diame-
ter at the site of needle insertion and partial thickness
associated with a small blister. The overall incidence of
matting and hyperpigmentation in the study (deter-
mined as the average score of the three investigators
experienced in sclerotherapy technique and complica-
tions) was 26.0% and 31.4%, respectively.
DISCUSSION
Sclerosing solutions used for sclerotherapy are
often associated with significant patient discomfort.
HS is a commonly used agent that is not only asso-
ciated with pain on injection, but also is associated
with cramping in a significant number of patients.
The cramping that can occur in the few minutes
after injection is usually short-lived. The initial pain
probably occurs when the solution contacts the
venous adventitial nerve fibers. Subsequent stimula-
tion of the periadventitial sympathetic nerve fibers
may lead to muscle contraction and, therefore,
cramping.3,4
In an effort to reduce the pain associated with the
use of HS, we have routinely added lidocaine to the
solution in our sclerotherapy practice. This appears to
be a common practice by many others today.1 In fact,
this author has noted several anesthesiologists who
routinely administer lidocaine intravenously before
injecting a potentially painful medication. In a review
of his own experience, Duffy reports that 82% of
patients experience significant discomfort and cramp-
ing with the use of HS.2 He suggests that lidocaine
added to the solution minimizes patient discomfort
during injection. Martin has also proposed that lido-
caine be added to the sclerosant to reduce the pain
associated with injection.5 Goldman, in his text on
sclerotherapy, discusses the issue of adding lidocaine
to HS.3
Despite the anecdotal experiences mentioned
above, there have been no studies in the literature
that objectively evaluate the effectiveness of lido-
caine when added to HS. The results of this study
show a statistically significant reduction in the pain
experienced by patients who received the solution
that included lidocaine.
The addition of lidocaine to HS poses some con-
cerns, however. Some have argued that this practice
creates a solution with allergic potential from a solu-
tion that had no such potential. Although this is the-
oretically true, most adverse events to lidocaine con-
sist of vasovagal reactions or toxic overdoses.3 True
allergic hypersensitivity or anaphylaxis to lidocaine is
extremely rare, and there are very few documented
cases of it, despite lidocaine’s widespread use
throughout the world.6,7,8 Some authors believe
that allergic hypersensitivity to lidocaine, and amide
local anesthetics in general, does not exist.9 Methyl
paraben, which is used as a preservative in multidose
vials of lidocaine, does have allergic potential and
could be responsible for some of the rare reported
instances of reactions. To minimize this risk, single
dose vials of lidocaine that are methyl paraben free
should be used.3 A review of the English literature
did not reveal any instances of lidocaine hypersensi-
tivity associated with sclerotherapy. Our personal
experience at the Kachelmacher Memorial Clinic in
several years with thousands of patients has not
revealed an episode of hypersensitivity believed to be
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Table IV. Pain scores versus vein size
Vein size 0 to Vein size 1 to
1 mm 3 mm P value
Pain score 1 3 6 .21
Pain score 2 to 3 15 11
Pain score 1 to 2 13 14 .48
Pain score 2 to 3 5 3
Table V. Photographic scores
HS (n = 19) LIDO (n = 16) P value
Disappearance 3.91 4.00 0.72
Pigmentation 3.51 3.71 0.26
Neovascularization 3.65 3.73 0.50
Overall score 11.07 11.43 0.41
HS, Hypertonic saline alone; LIDO, hypertonic saline with lidocaine.
caused by lidocaine. Despite this, patients should be
apprised that there may be added risk with the use of
lidocaine in the sclerosant.
Another criticism of the addition of lidocaine to
HS is that the overall effectiveness of the solution
may be decreased through dilution. The results of
the current study showed that the effectiveness of
the solutions was similar (as demonstrated by means
of equivalent photographic scores) and thus do not
support this contention. Sadick studied the effect of
varying HS concentrations on the efficacy of treat-
ment.10 He found that 11.7% saline was the minimal
effective concentration. In this study, the addition of
lidocaine resulted in a saline concentration of 19%,
which is well above the minimal concentration sug-
gested by Sadick.
If one looks at the individual components of the
photographic score (Table IV), it can be seen that
there are no significant differences in the incidence
of pigmentation and matting/neovascularization
between the two groups. The overall incidence of
pigmentation and matting in both groups was 31.4%
and 26.0%, respectively. Duffy reports incidences of
pigmentation and matting of 30% and 35%, respec-
tively.2 These incidences compare closely with the
results of the current study. Although complication
rates approaching 30% may seem rather high, Weiss
suggests that these are temporary phenomena, and
70% to 80% spontaneous resolution can be expected
within six months.11
Thrombosis occurred equally in both groups in
the current study, with an overall incidence of 22.9%.
This does seem abnormally high; Duffy reported an
incidence of 0.5% in his study.2 However, most
thrombi were small, ranging in length from 1 to 3
mm, and only one thrombus was larger than this (1
cm). This thrombus underwent microthrombectomy
because of the patient’s discomfort. The remainder
of the thrombi resolved on their own during the
course of the follow-up period.
CONCLUSIONS
HS is one of the more popular sclerotherapy
solutions in use today. There are many reasons for
this. It is inexpensive and readily available. It is effec-
tive, and resolution of varicosities occurs rapidly. In
addition, unlike many of the other solutions avail-
able, it has no potential for allergic reactions. The
most troubling disadvantages of the solution are its
association with cutaneous necrosis and its propensi-
ty for discomfort on the part of the patient. The first
problem can be overcome, for the most part, by
close attention to proper technique on the behalf of
the sclerotherapist. Our study demonstrates that the
concern about patient discomfort can be addressed
by the addition of lidocaine to the HS, without sac-
rificing the effectiveness of treatment. Objections
based on the possible increased allergenicity of the
solution have not been borne out in the literature.
We thank the staff of the Kachelmacher Memorial
Clinic and Kim Hasselfeld from the Department of
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